Evidence map›Paper›PMID 29526181›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2018

[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer].

Li Sun, Zhicheng Xiong, Chengbo Han

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Li SunDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, China.
Zhicheng XiongDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, China.
Chengbo HanDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, series of driver genes, such as EGFR, KRAS/NRAS, BRAF, PIK3CA, ALK and ROS1 and so on, have been found in non-small cell lung cancer (NSCLC) one after another with the development of molecular detecting technology. Targeted drugs bring benefits for these NSCLC patients with driver gene variations. However, some NSCLC did not have any known driver gene variations; we called it pan-negative lung cancer. In this paper, we summarize the concept, clinical pathological characteristics, the epidemiological characteristics, treatment and prognosis of pan-negative NSCLC.

Indexed as

MutationCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsPrognosisDriver geneLung neoplasmsPan-negative

Identifiers

PMID29526181
PMCPMC5973015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.